Phoenix Financial’s Blueprint Medicines BPMC Stock Holding History

Phoenix Financial’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,825	Closed	-$916K	–	317
2021 Q1	$916K	Buy	+9,825	New	+$981K	0.02%	287

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Phoenix Financial's BPMC Position: Q2 2021 in Review

Phoenix Financial sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 9,825 shares — an estimated $916K sold.

Phoenix Financial first reported a position in BPMC in Q1 2021 and held it in 1 quarter. The position peaked at $916K in Q1 2021. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

Phoenix Financial reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
Phoenix Financial sold 9,825 Blueprint Medicines shares in Q2 2021, an estimated $916K.
Phoenix Financial first reported a position in Blueprint Medicines in Q1 2021 and held it in 1 quarter.
Phoenix Financial's Blueprint Medicines position peaked at $916K in Q1 2021.
281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Phoenix Financial's 13F filing for Q2 2021, filed 10 Aug 2021.